Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Definitions

• the present invention provides a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.
• Nilotinib is chemically, 4-methyl-N-[3-(4-methyl-lH-imidazol-l-yl)-5- (lTifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide and has the structural formula:
• Nilotinib is a tyrosine kinase inhibitor used for the treatment of drug-resistant chronic myelogenous leukemia (CML), and in particular, for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients whose disease has progressed on or who cannot tolerate other therapies that included imatinib.
• CML chronic myelogenous leukemia
• Nilotinib is administrated as a hydrochloride salt in forms of capsules that are marketed in the USA and the EU under the name Tasigna®.
• Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice.
• polymorphs are different crystalline forms of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules.
• Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
• Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
• XRD X-ray diffraction
• DSC Differential Scanning Calorimetry
• IR Infrared spectrometry
• Solvent medium and mode of crystallization play very important role in obtaining a crystalline form over the other.
• Nilotinib and its hydrochloride salt can exist ' in different polymorphic forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
• Nilotinib hydrochloride and its salts were disclosed in U.S. patent no. 7,169,791.
• crystalline form A of nilotinib hydrochloride was characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at about 8.5, 11.0, 11.5, 18.8, 19.2, 20.8, 22.1 and 26.0 degrees.
• PCT publication no. WO 2010/054056 disclosed crystalline form Tl, form T2, form T3, form T4, form T5, form T6, form T7, form T8, form T9, form T10, form Ti l, form T12, form T13, form T14, form T15, form T16, form T17, form T18 and form T19 of nilotinib hydrochloride.
• crystalline form T2 of nilotinib hydrochloride was characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at about 7.1, 8.7, 11.5, 14.0, 15.3, 16.6, 17.4, 19.4 and 25.5 ⁇ 0.2 degrees.
• crystalline form T3 of nilotinib hydrochloride was characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at about 7.0, 8.5, 11.4, 12.1, 14.2, 17.2, 19.2, 22.1, 23.2 and 25.2 ⁇ 0.2 degrees.
• crystalline form Ti l of nilotinib hydrochloride was characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at about 7.4, 8.7, 17.4, 25.3, 26.2 and 35.1 ⁇ 0.2 degrees.
• crystalline form T13 of nilotinib hydrochloride was characterized by an X-ray powder diffraction pattern having peaks expressed as 2 ⁇ at about 8.2, 12.8, 15.7, 16.5, 21.7 and 23.9 ⁇ 0.2 degrees.
• an object of the present invention is to provide a novel crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical compositions comprising it.
• the present invention provides a crystalline form of nilotinib hydrochloride designated as form HI characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 8.6, 11.4, 13.2, 14.3, 15.5, 17.3, 19.2 and 25.3 ⁇ 0.2 degrees.
• the present invention provides a process for the preparation of nilotinib hydrochloride crystalline form HI, which comprises:
• step (a) heating the contents obtained in step (a) at above 65°C;
• step (b) adding a solution of hydrochloride in an ester solvent to the solution obtained in step (b) at above 65°C;
• step (c) maintaining the solution obtained in step (c) at above 65°C;
• the present invention provides a process for the preparation of nilotinib hydrochloride crystalline form HI, which comprises freez drying an aqueous solution of nilotinib hydrochloride at -80 to -90 deg C to obtain nilotinib hydrochloride crystalline form HI.
• the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising crystalline form HI of nilotinib hydrochloride and pharmaceutically acceptable excipients.
• Figure 1 is an X-ray powder diffraction spectrum of nilotinib hydrochloride crystalline form HI .
• X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X- ray powder diffractometer having a copper- ⁇ radiation. Approximately lgm of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.02 degrees to theta per step and a step of 10.8 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
• room temperature refers to a temperature of about 25°C to about 35°C.
• a crystalline form of nilotinib hydrochloride designated as form HI characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 8.6, 11.4, 13.2, 14.3, 15.5, 17.3, 19.2 and 25.3 ⁇ 0.2 degrees.
• the powdered x-ray diffractogram (PXRD) of nilotinib hydrochloride crystalline form HI is shown in figure 1.
• the nilotinib hydrochloride crystalline form HI may be identified and differentiated from the known polymorphs by its characteristic PXRD pattern.
• a peak at 25.3 ⁇ 0.2 degrees 2 ⁇ is present and a peak at 11.0 ⁇ 0.2 degrees 2 ⁇ is absent in the PXRD of the nilotinib hydrochloride crystalline form HI of the present invention, but the peak at 25.3 ⁇ 0.2 degrees 2 ⁇ is absent and a peak at 11.0 ⁇ 0.2 degrees 2 ⁇ is present in the PXRD of the nilotinib hydrochloride crystalline form A disclosed in the '870 patent.
• peaks at 7.1 and 26.3 degrees 2 ⁇ are absent in the PXRD of the crystalline form HI of the present invention, but are present in the PXRD of the crystalline form T2 disclosed in the '056 patent.
• peaks at 7.0, 22.1 and 23.2 degrees 2 ⁇ are absent in the PXRD of the crystalline form HI of the present invention, but are present in the PXRD of the crystalline form T3 disclosed in the '056 patent.
• peaks at peaks at 11.3 and 13.2 are present and 7.4, 26.2 and 35.1 degrees 2 ⁇ are absent in the PXRD of the crystalline form HI of the present invention, but are peaks at peaks at 11.3 and 13.2 are absent and 7.4, 26.2 and 35.1 degrees 2 ⁇ are present in the PXRD of the crystalline form Tl 1 disclosed in the '056 patent.
• peaks at peaks at 8.6, 13.2 and 25.3 are present and 8.2, 12.8 and 23.9 degrees 2 ⁇ are absent in the PXRD of the crystalline form HI of the present invention, but are peaks at peaks at 8.6, 13.2 and 25.3 are absent and 8.2, 12.8 and 23.9 degrees 2 ⁇ are present in the PXRD of the crystalline form T13 disclosed in the ⁇ 56 patent.
• a process for the preparation of nilotinib hydrochloride crystalline form HI which comprises: a) suspending nilotinib in an alcoholic solvent;
• step (a) heating the contents obtained in step (a) at above 65°C;
• step (b) adding a solution of hydrochloride in an ester solvent to the solution obtained in step (b) at above 65°C;
• step (c) maintaining the solution obtained in step (c) at above 65°C;
• the alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropanol, 2-butanol, 2-methyl-2-butanol and n-pentanol, and more preferably the alcoholic solvents are ethanol and 2-methyI-2- butanol.
• Step (b) may preferably be carried out at about 65 to 100°C and more preferably at about 70 to 80°C.
• the ester solvent used in step (c) may preferably be a solvent or mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate, and more preferably the ester solvent is ethyl acetate.
• step (c) may preferably be carried out at about 65 to 100°C and more preferably at about 70 to 80°C.
• the reaction in step (b) may preferably be carried out at about 65 to 100 C and more preferably at about 70 to 80°C.
• Step (d) may preferably be maintained at about 70 to 80°C.
• Isolation of nilotinib hydrochloride crystalline form HI in step (e) can be performed by conventional methods such as cooling, removal of solvents, concentrating the reaction mass, extraction with a solvent and the like.
• a process for the preparation of nilotinib hydrochloride crystalline form HI which comprises freez drying an aqueous solution of nilotinib hydrochloride at -80 to -90 deg C to obtain nilotinib hydrochloride crystalline form H 1.
• a pharmaceutical composition comprising crystalline form HI of nilotinib hydrochloride and pharmaceutically acceptable excipients, and optionally other therapeutic ingredients.
• the crystalline form HI may preferable be formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms.
• Nilotinib (3 gm) as obtained in example 1 was suspended in ethanol (120 ml) and then heated to reflux. A solution of hydrochloric acid in ethyl acetate (4 ml) was added to the solution at reflux and stirred for 1 hour at reflux. The ethanol solvent was distilled off under vacuum to obtain a residual mass. To the residual mass was added ethyl acetate (50 ml) and then cooled to room temperature. The reaction mass was stirred for 1 hour at room temperature and filtered. The solid obtained was dried to give 3 gm of nilotinib hydrochloride crystalline form HI.
• Example 3 Example 3:
• Nilotinib (3 gm) was suspended in 2-methyl-2-butanol (120 ml) and then heated to 70°C. A solution of hydrochloric acid in ethyl acetate (4 ml) was added to the solution at 70°C. The solution was stirred for 30 minutes at 70°C and then cooled to room temperature. The contents were further cooled to 10°C and maintained for 1 hour at
• Nilotinib (2 gm) was added to a mixture of water (20 ml) and concentrated hydrochloric acid (0.42 ml) at room temperature to obtain a clear solution. The solution was subjected to freez drying at about -80 deg C for 8 hours to obtain 2 gm of nilotinib hydrochloride crystalline form HI.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (2)

Family

ID=46146222

Family Applications (1)

Country Status (4)

Cited By (8)

Families Citing this family (4)

Family Cites Families (13)

• 2011
  • 2011-11-11 IN IN3577CH2010 patent/IN2010CH03577A/en unknown
  • 2011-11-11 WO PCT/IN2011/000779 patent/WO2012070062A2/en not_active Ceased
  • 2011-11-11 US US13/989,602 patent/US8703788B2/en not_active Expired - Fee Related
  • 2011-11-11 EP EP11843202.0A patent/EP2648519A4/en not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events